Experimental Serotonergic Agents for the Treatment of Schizophrenia
Open Access
- 1 February 2021
- journal article
- review article
- Published by Taylor & Francis Ltd in Journal of Experimental Pharmacology
- Vol. ume 13, 49-67
- https://doi.org/10.2147/jep.s259317
Abstract
Abstract: Schizophrenia remains one of the most chronic and highly disabling mental disorder. To date, the pathomechanism of schizophrenia is not fully understood and current treatments are characterized by some limitations. First- and second-generation antipsychotics have shown clinical efficacy in treating positive symptoms, while are poorly effective on both negative symptoms and cognitive deficits. Moreover, they can involve many metabolic and neurological side effects, leading to low therapeutic compliance. Many evidence suggested that serotonin may play a complex role in the neurobiology of schizophrenia. Therefore, new drugs targeting 5-HT receptors (5-HTRs) have become an important area of research in schizophrenia in the hope that treatment efficacy may be improved without inducing side effects observed with currently available antipsychotics. Research using the main database sources was conducted to obtain an overview of preclinical and clinical pharmacological 5-HTR-targeted therapies in patients with schizophrenia. We identified 17 experimental serotonergic agents, under study for their potential use in schizophrenia treatment. Particularly, AVN-211, LuAF-35700 and Brilaroxazine are currently under clinical development. Moreover, some compounds showed some pro-cognitive and antipsychotic-like properties in animal models, while other agents showed contradictory effects in improving symptoms and were removed from the development program. Although some serotonergic drugs seem promising for improving the treatment of schizophrenia, further studies regarding the pathophysiological mechanisms of schizophrenia and novel compounds as well as high-quality trials are necessary in order to improve schizophrenia outcomes.Keywords
This publication has 51 references indexed in Scilit:
- 5‐HT6 receptor agonists and antagonists enhance learning and memory in a conditioned emotion response paradigm by modulation of cholinergic and glutamatergic mechanismsBritish Journal of Pharmacology, 2012
- Contribution of SPECT Measurements of D2and 5-HT2AOccupancy to the Clinical Development of the Antipsychotic SB-773812Journal of Nuclear Medicine, 2011
- Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in ratsInternational Journal of Neuropsychopharmacology, 2010
- SchizophreniaBMJ, 2007
- Antipsychotic efficacy: Relationship to optimal D2-receptor occupancyEuropean Psychiatry, 2007
- Selective Serotonin Reuptake Inhibitor (SSRI) Add-On Therapy for the Negative Symptoms of SchizophreniaBritish Journal of Psychology, 2007
- SB-699551-A (3-cyclopentyl-N-[2-(dimethylamino)ethyl]-N-[(4′-{[(2-phenylethyl)amino]methyl}-4-biphenylyl)methyl]propanamide dihydrochloride), a novel 5-ht5A receptor-selective antagonist, enhances 5-HT neuronal function: Evidence for an autoreceptor role for the 5-ht5A receptor in guinea pig brainNeuropharmacology, 2006
- Effects of novel antipsychotics with mixed D2 antagonist/5-HT1A agonist properties on PCP-induced social interaction deficits in the ratNeuropharmacology, 2005
- 8-OH-DPAT-induced effects on prepulse inhibition: Pre- vs. post-synaptic 5-HT1A receptor activationPharmacology Biochemistry and Behavior, 2005
- [3H]-8-OH-DPAT binding in the rat brain raphe area: involvement of 5-HT1Aand non-5-HT1AreceptorsBritish Journal of Pharmacology, 2000